1)日本リウマチ学会ホームページ:http://www.ryumachi-jp.com/info/120115_table1.pdf
2)Kaneko Y, Hanaoka H, Hirakata M, et al:Distinct arthropathies of the hands in patients with anti-aminoacyl tRNA synthetase antibodies: usefulness of autoantibody profiles in classifying patients. Rheumatology (Oxford), 2014, in press
3)Askling J, Fored CM, Brandt L, et al:Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 66:1339-1344,2007
4)Efficacy of various durations of isoniazid preventive therapy for tuberculosis:five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 60:555-564,1982
5)日本肝臓学会,肝炎診療ガイドライン作成委員会(編):B型肝炎治療ガイドライン(第1.2版),2013(http://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_b)
6)Harigai M, Koike R, Miyasaka N, et al:Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 357:1874-1876,2007
7)Mori S, Sugimoto M:Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis. Rheumatology (Oxford) 51:2120-2130,2012
8)Hoshino J, Ubara Y, Hara S, et al:Outcome and treatment of bucillamine-induced nephropathy. Nephron Clin Pract 104:c15-c19,2006
9)Almoallim H, Al-Ghamdi Y, Almaghrabi H, et al:Anti-Tumor Necrosis Factor-α Induced Systemic Lupus Erythematosus. Open Rheumatol J 6:315-319,2012
10)Nakajima A, Saito K, Kojima T, et al:No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan. Mod Rheumatol 23:945-952,2013
11)Chiba N:The incidence of cancer among Japanese patients with rheumatoid arthritis on 2003 obtained by using Ninja [abstract]. Mod Rheumatol 16(Suppl):202,2006
12)Baecklund E, Iliadou A, Askling J, et al:Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692-701,2006
13)del Rincón ID, Williams K, Stern MP, et al:High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737-2745,2001
14)Jacobsson LT, Turesson C, Gülfe A, et al:Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32:1213-1218,2005
15)Solomon DH, Avorn J, Katz JN, et al:Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 54:3790-3798,2006